Intra Cellular Therapies | Betriebsergebnis



Betriebsergebnis Veränderung Datum
Acadia Pharmaceuticals USD 35.76M 3.38M 2025-09
ALKERMES USD 89.08M 3.9M 2025-09
BioCryst Pharmaceuticals USD -2.54M 10.23M 2024-12
Biogen USD 659.6M 192.2M 2025-09
Bristol-Myers Squibb USD 4.2B 562M 2025-12
Cytokinetics USD -166.76M 55.25M 2025-09
Esperion Therapeutics USD -16.03M 18.6M 2024-09
Gilead Sciences USD 2.96B 551M 2025-12
Halozyme Therapeutics USD -88.41M 306.33M 2025-12
J&J USD 5.59B 1.81B 2025-12
Minerva Neurosciences USD -21.85M 17.48M 2024-12
Nektar Therapeutics USD -34.34M 15.43M 2024-09
Neurocrine Biosciences USD 227.9M 11.4M 2025-12
Novartis USD 4.58B 879M 2025-09
Prothena USD -39.76M 12.25M 2025-09
RedHill Biopharma USD -4.22M 1.8M 2024-06
Supernus Pharmaceuticals USD -60.18M 72.32M 2025-09
United Therapeutics USD 389.3M 112.4M 2025-09
Vanda Pharmaceuticals USD -40.66M 29.66M 2024-12


Intra Cellular Therapies Betriebsergebnis - Diese Werte, historische Daten, Prognosen, Statistiken, Diagramme und ökonomische Kalender - Feb 2026.